CClinicalTrials.gg
Status unknownNCT04554186Updated Sep 23, 2020

Serratus Anterior Plane Block Versus Thoracic Paravertebral Block.

An interventional study of Serratus anterior plane block and Thoracic Paravertebral block in Rib Fractures and Analgesia, sponsored by Minia University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-09-23.

Sponsored by Minia University · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Compare between serratus anterior plane block and thoracic Paravertebral block in analgesia for patients with multiple rib fractures

Read the detailed description

The study will be conducted in a prospective randomised controlled. Patients will be allocated into three groups

Control group:

The patient will receive fentanyl patch 50 microgram

TPVB group:

The patient will receive thoracic vertebral plane lock 0.4ml/kg bupivacaine 0.1 25% will be administered. For continuous infusion catheter will be inserted . Then a rate of 7ml / hour to max 10 ml / hour of bupivacaine 0.0625%

SAPB group,:

Patient will receive serratus anterior plane block 0.4ml / kg bupivacaine 0.125% will be injected to open the space then a catheter will be advanced For continuous infusion of 0.0625 % bupivacaine at 7 ml / hour

02

Conditions studied

  • Rib Fractures
  • Analgesia

Keywords

  • Fracture rib
  • TPVB
  • SAPB
03

In context

Fractures, Bone

2,261 studies on the registry are indexed under Fractures, Bone; 325 are open to participants now.

This study's planned enrollment of 60 is below the median of 69 across 1,482 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Minia University is the lead sponsor of 356 studies on the registry; 115 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ASA 1_3 Age 18_60 Unilateral fracture ribs

Exclusion criteria

Exclusion Criteria:

  • Drug allergy Morbid obese Opioid dependence Patients refuse
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Serratus anterior plane block

    20 patients will receive SAP block with 0.4 ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%

    Procedure: Serratus anterior plane block

  • Active comparator
    Thoracic Paravertebral block

    20 patients will receive TPVB 0.4ml / kg bupivacaine 0.125% then continuous infusion through a catheter at rate of 7 ml / hour to max 10 ml / hour of bupivacaine 0.0625%

    Procedure: Thoracic Paravertebral block

  • Placebo comparator
    Control group

    20 patients will receive Fentanyl patch 50 microgram

    Procedure: Control

Interventions

  • ProcedureSerratus anterior plane block

    Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound

  • ProcedureThoracic Paravertebral block

    Injection of bupivacaine in the thoracic Paravertebral space using ultrasound

  • ProcedureControl

    Place a fentanyl patch 50 microgram

06

What researchers measure

Primary outcomes

  1. VAS score

    Visual analogue pain score describe by the patient

    Time frame: 24 hour

Secondary outcomes

  1. Total analgesic consumption

    Total opioid consume by the patient in 24 hour

    Time frame: 24 hour

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04554186
Lead sponsor
Minia University
Responsible party
Ahmed Gamal Shehata (Assistant lecturer, Minia University) — Principal investigator
First posted
Sep 18, 2020
Start date
Sep 22, 2020
Primary completion
Jan 1, 2021 (estimated)
Completion
Jan 15, 2021 (estimated)
Last update
Sep 23, 2020

Study contacts

Ahmed G Shehata, Master
Contact
ahmedgamalicu@gmail.com
1067622270 ext. 0020
Omyma M Shehata, MD
Contact
Omyma.shehata44@yahoo.com
1061762894 ext. 0020
Amany K Aboelhassan
study chair · Minia University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion